OPTN News and Press, OptiNose Inc.

YARDLEY, Pa., June 27, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that XHANCE ® (fluticasone propionate) has been added to Express Scripts’ nationa...

2024-05-17 20:55:21 ET OptiNose, Inc. (OPTN) Q1 2024 Results Conference Call May 15, 2024 10:00 AM ET Company Participants Jonathan Neely - VP, IR & Business Development Dr. Ramy Mahmoud - CEO Conference Call Participants Thomas Flaten - Lake Street C...

YARDLEY, Pa., May 17, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the H.C...

2024-05-15 10:30:03 ET Lake Street analyst issues BUY recommendation for OPTN on May 15, 2024 08:43AM ET. The previous analyst recommendation was Buy. OPTN was trading at $1.13 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analy...

2024-05-14 07:25:51 ET More on OptiNose OptiNose, Inc. 2023 Q4 - Results - Earnings Call Presentation OptiNose, Inc. (OPTN) Q4 2023 Earnings Call Transcript OptiNose granted FDA nod to expand labeling for sinusitis therapy Seeking Alpha’s Quant Rating ...

Company reports Q1 2024 XHANCE net revenue of $14.9 million, an increase of 26% compared to Q1 2023 Company expects full year 2024 XHANCE net revenues to be between $85.0 to $95.0 million Company expects peak year XHANCE net revenues of at least $300 million from current special...

YARDLEY, Pa., May 10, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the Company will report financial results for the first quarter 2024 and corporate updates, before...

2024-05-09 08:32:43 ET More on pre-market losers & stocks. Soluna launches new AI cloud service, shares jump IPO Roundup: Rubrik, Marex Group, Loar Holdings, and more Financial information for Davis Commodities Limited Financial information for Neo-Concep...

Led by Nantahala Capital and The D. E. Shaw Group with participation from existing and new investors Post-offering cash balance of ~$100 million expected to fund operating plan through 2025 Company expects XHANCE net revenues to be between $85 to $95 million for full year 2024 ...

2024-05-06 08:39:30 ET More on premarket gainers & stock CytomX: CX-904 Tumor Treatment Data Might Get Ball Rolling CytomX Therapeutics: I'm Bullish; There's More Than One Masked Immunotherapy Company In Town NRX Pharmaceuticals, Inc. (NRXP) Q4 2023 Earnings Call...